In addition to their antihyperglycemic effects and concurrent lower risk of hypoglycemia, the GLP-1 receptor agonists and SGLT2 inhibitors demonstrated significant benefits for patients with atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease [6,7]. Here, SLC5A2 is linked to chronic kidney disease.